|
|
Blood, 15 July 2005, Vol. 106, No. 2, pp. 658-667.
Prepublished online as a Blood First Edition Paper on March 22, 2005; DOI 10.1182/blood-2004-09-3585.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/ v 3 in promyelocytic leukemia NB4 cells
Anne Saumet,
Mouna Ben Slimane,
Michel Lanotte,
Jack Lawler, and
Véronique Dubernard
From the Institut National de la Santé et de la Recherche Médicale, INSERM U-685, Paris, France; Centre de Recherche sur les Maladies du Sang et Virologie Expérimentale de l'Association Claude Bernard, Hôpital Saint-Louis, Paris, France; and Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
By means of its antiangiogenic activity, thrombospondin-1 (TSP-1) exerts indirect antitumoral action on solid tumors. Here, we investigated potential antitumor action in an in vitro cell model for promyelocytic leukemia (NB4-LR1), resistant to retinoid maturation. Purified soluble TSP-1 added to cultures induced a strong dose-dependent growth inhibition and a slowly developing maturation-independent cell death. Recombinant fragments of TSP-1 allowed mapping of these activities to its type 3 repeat/C-terminal domain, features that are distinct from those of TSP-1 action on solid tumors, previously ascribed to the type 1 repeat domain. Cell death in leukemia was characterized as a caspase-independent mechanism, without DNA fragmentation, but phosphatidylserine externalization followed by membrane permeabilization. Mitochondria membrane depolarization was inherent to TSP-1 action but did not produce release of death-promoting proteins (eg, noncaspase apoptosis regulators, apoptosis-induced factor [AIF], endonuclease G, or Omi/HtrA2 or the caspase regulators, cytochrome c or second mitochondrial activator of caspase/direct inhibitor of apoptosis protein-binding protein with low isoelectric point [Smac/DIABLO]). Although detected, reactive oxygen species (ROS) production was likely not involved in the death process. Finally, receptor agonist RFYVVM and RGD peptides indicated that TSP-1 death effects are mediated by membrane receptors CD47 and v 3. These results demonstrated a new domain-specific antitumoral activity of TSP-1 on a leukemia cell line, which extends TSP-1 therapeutic potential outside the area of vascularized solid tumors. (Blood. 2005;106:658-667)

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. A. Pallero, C. A. Elzie, J. Chen, D. F. Mosher, and J. E. Murphy-Ullrich
Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis
FASEB J,
November 1, 2008;
22(11):
3968 - 3979.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bras, V. J. Yuste, G. Roue, S. Barbier, P. Sancho, C. Virely, M. Rubio, S. Baudet, J. E. Esquerda, H. Merle-Beral, et al.
Drp1 Mediates Caspase-Independent Type III Cell Death in Normal and Leukemic Cells
Mol. Cell. Biol.,
October 15, 2007;
27(20):
7073 - 7088.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Krispin, Y. Bledi, M. Atallah, U. Trahtemberg, I. Verbovetski, E. Nahari, O. Zelig, M. Linial, and D. Mevorach
Apoptotic cell thrombospondin-1 and heparin-binding domain lead to dendritic-cell phagocytic and tolerizing states
Blood,
November 15, 2006;
108(10):
3580 - 3589.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Inglefield, C. J. Larson, S. J. Gibson, H. Lebrec, and R. L. Miller
Apoptotic Responses in Squamous Carcinoma and Epithelial Cells to Small-Molecule Toll-like Receptor Agonists Evaluated with Automated Cytometry
J Biomol Screen,
September 1, 2006;
11(6):
575 - 585.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. van Amerongen and A. Berns
TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes?
Genes & Dev.,
August 1, 2006;
20(15):
1975 - 1981.
[Full Text]
[PDF]
|
 |
|
|
|